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The phasing Out of chlorofluorocarbons (CFCs) requires the development of an alternative non-ozone depleting 
propellant for use in pressurized metered dose inhalers (pMDls). The present study assessed the effects on 
tolerability and efficacy of a switch from the currently available formulation containing the CFC propellants 11 and 
12 to an alternative non-CFC formulation using the propellant hydrofluoroalkane (HFA) 134a in patients with 
mild to moderate asthma. 
After a 4-week run-in period during which patients received salbutamol 2001~g four times daily from a CFC 
pMDI, 547 patients were randomized to 12 weeks of treatment with salbutamol 200/~g four times daily 
administered from either an HFA 134a pMDI (Ventolin TM CFC-free; 277 patients) or CFC pMDI (Ventolin TM, 
270 patients). At the end of this period, all patients then received a further 4 weeks of treatment with the same dose 
of salbutamol via a CFC pMDI (run-out period). On the basis that high doses of fl2-agonists are known to increase 
heart rate, change in heart rate was selected as the primary outcome variable. 
Small increases in heart rate were observed uring the treatment period and these changes were comparable in
both groups; the 90% confidence interval for the treatment differences was within the predefined limits for clinical 
equivalence (+ 10 beats min-l) .  The incidence of adverse vents was similar in both groups and there were no 
reports of paradoxical bronchospasm. Furthermore, daily PEF measurements showed comparability in terms of 
lung function. Symptom scores and use of additional bronchodilator were also similar in both groups. 
These results demonstrate that salbutamol (800/~g day-t) ,  formulated with HFA 134a is equivalent o the 
current CFC formulation in terms of tolerability and efficacy. 
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Introduction 
Tl?e short-acting fl2-agonist albutamol iswidely used in the 
treatment of asthma and is available in a pressurized 
metered ose inhaler (pMDI) in over 90 countries world- 
wide. For some time, asthma treatment guidelines have 
recommended that short-acting fl2-agonists should only be 
used on an as-required basis for symptomatic relief (I,2). 
However, it is acknowledged that in many countries 
salbutamol continues to be used on a regular basis. It is 
therefore ssential that salbutamol reformulated with the 
non-chlorofluorocarbon (CFC) propellant hydrofluoroalk- 
ane (HFA) 134a and administered at the maximum 
Received 13 December 1999 and accepted in revised form 29 
February 2000. 
Correspondence should be addressed to: Mr Andrew Sykes, 
Respiratory Therapeutic Development Group, Glaxo Wellcome 
Research and Development, Stockley Park, Uxbridge, Middlesex, 
UBll IBT, U.K. Fax: +44 (0) 20 8990 8389 
recommended daily dose (800~ug day-t) ,  should be as safe 
and effective as the currently marketed CFC product. In 
addition, regular dosing is the most relevant method of 
assessing the safety profile of salbutamol. 
This stu.dy was conducted to compare the tolerability and 
efficacy of an HFA 134a formulation of salbutamol 800 Fg 
day- I  (VentolinTM CFC-free) with the current salbutamol 
CFC pMD1 (containing propellants 11 and 12; Ventolin TM) 
at the same daily dosage in patients with mild to moderate 
asthma. 
Methods  
PATIENTS 
Adult patients aged >18 years were enrolled from out- 
patients clinics at 42 centres in eight Eastern European 
countries (Bulgaria, Croatia, Czech Republic, Hungary, 
Poland, Russia, Slovakia and Slovenia). 
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All patients had regularly used short acting/32-agonists 
for at least 4 weeks prior to the study and could 
demonstrate correct use of a pMDI. In addition they had 
a forced expiratory volume in l sec (FEV~) of 50-100% of 
the predicted normal value and either a documented history 
in the past 12 months of a 15% reversibility in FEVt after 
inhalation of a fl2-agonist or demonstrable r versibility :at 
the screening visit. 
Patients were excluded from the study if they had 
unstable asthma, asthma requiring hospitalization or had 
used parenteral corticosteroids or antibiotics in the 
previous 4 weeks; had used a long-acting or oral/32-agonist 
in the previous 2 weeks; had used oral or parenteral 
corticosteroids on two or more occasions in the previous 4
months; were hypersensitive to /32-agonists, pregnant (or 
taking inadequate contraceptive precautions); or had a 
smoking history equivalent to 20 pack-years. 
In addition to the above criteria, only patients who had 
used up to four actuations of rescue salbutamol (in addition 
to the standard osage) on any day during the last 2 weeks 
of the 4-week run-in period were allowed to enter the study. 
The study was granted ethics and regulatory approval by 
the relevant committees and written informed consent was 
obtained from each patient before they participated in the 
study. 
STUDY DESIGN 
This was a multicentre, double-blind, randomized, parallel- 
group study. During a 4-week run-in period the patients' 
usual inhaled short-acting bronchodilator was replaced 
with salbutamol 200#g four times daily delivered by a 
pMDI propelled by the CFC propellants 11 and 12. 
Patients were also issued with a commercially available 
salbutamol inhaler to use as required for symptomatic 
relief. At the end of the run-in period, patients were 
randomized to receive four daily doses of salbutamol 200 t(g 
formulated either with the CFC propellants 11 and 12, or 
with HFA 134a, for 12 weeks. This was followed by a 4- 
week 'run-out' period when all patients received salbutamol 
200pg four times daily formulated with the CFC propel- 
lants 11 and 12. A large volume spacer device (Voluma- 
tic TM) was supplied to those patients who required one. 
Throughout he study patients could continue to use 
other asthma medication with the exception of all /32 -
agonists, any combination product containing a/32-agonist, 
or parenteral or depot corticosteroids. 
Patients attended the clinic on eight scheduled occasions: 
at the start, middle and end of the 4-week run-in period; 
after 1, 6 and 12 weeks of treatment; and at weeks 1 and 4 
of the run-out period. 
EFFICACY MEASUREMENTS 
Patients were given a mini-Wright peak flow meter to use at 
home and were asked to record the best of three 
measurements of morning and evening peak expiratory 
flow (PEF) on a daily record card. Other parameters 
recorded on the daily record card were daytime symptoms 
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using a six-point scale (0 = no symptoms; 5 = symptoms o 
severe that the patient was unable to perform normal daily 
activities); night-time symptoms using a five-point scale 
(0 = no symptoms; 4= symptoms so severe that the patient 
was unable to sleep); and use of rescue salbutamol. 
FEVI and PEF (highest of three measurements) were 
recorded after the first dose of study medication and at each 
clinic visit. Where possible, all lung function assessments 
were made at the same time of day, preferably in the 
morning, and patients were requested to refrain from using 
their salbutamol for at least 4 h beforehand. 
SAFETY 
The study aimed to evaluate the tolerability of salbutamol 
on switching from a CFC to an HFA formulation. Heart 
rate, the primary outcome parameter, was measured at each 
clinic visit. Venous blood and urine samples were collected 
at the end of the run-in and treatment periods for standard 
haematological nd biochemical analysis. Samples were 
taken from fasted patients between 08.00 and 10.00 hours. 
Vital signs, electrocardiogram (ECG) and blood pressure 
were recorded at all clinic visits except at week 6 of the 
treatment period. 
STATISTICAL ANALYSIS 
The analysis was performed on all patients who had 
received at least one dose of study medication (intent-to- 
treat population). Hypothesis tests looked for equivalence 
between the two formulations of salbutamol. Equivalence is 
defined as the maximum acceptable difference between 
formulations for them still to be considered as equivalent 
(3). In this study, equivalence was established if the 90% 
confidence interval (CI) for the treatment difference in mean 
heart rate, the primary tolerability variable, was within 
_ 10 beats min-~. To provide adequate patient exposure 
for adverse vent reporting, it was planned to recruit 600 
patients to obtain data from 400 randomized patients. 
The change in heart rate from baseline was analysed 
using analysis of covariance (ANCOVA). Covariates used 
in the model were baseline, age, sex and treatment. 
For diary card variables, the change from baseline (mean 
value recorded uring the last week of the run-in period) 
was recorded for defined periods during the study. Analyses 
were performed on the change from baseline for each PEF 
variable using ANCOVA as above. 
Clinic lung function and the change in PEF after the 
first dose of study medication were also analysed using 
ANCOVA. Symptom scores and use of additional broncho- 
dilator medication were analysed using the Wilcoxon rank 
sum test stratified by centre using the Van Elteren extension 
(4). The resulting 90% CI was based on the unstratified 
Wilcoxon rank sum test. 
RESULTS 
Of the 547 patients randomized to receive study treatment, 
277 received salbutamol propelled by HFA 134a and 270 
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received salbutamol propelled by the CFC propellants 11 
and 12. The two treatment groups were well matched "in 
terms of baseline demographics (Table 1). Nineteen patients 
were withdrawn after randomization (12 in the HFA 134a 
pMDI group and seven in the CFC pMDI group). The 
majority of patient withdrawals were attributable to 
adverse events of respiratory origin (eight and three 
patients, respectively) and none of these were judged to 
be related to study treatment. One patient was withdrawn 
because of palpitations which were considered by the 
investigator as 'probably' related to treatment. 
HEART RATE 
Patients in both groups experienced a slight increase in 
mean heart rate, during the treatment period possibly 
reflecting improved compliance with regular treatment as 
part of a clinical trial. After 12 weeks of treatment, he 
mean change in heart rate from baseline was 2 beats min-1 
in the HFA 134a pMDI group and 1 beat min- t in the CFC 
pMDI group. Similar increases were reported at the end of 
the first week of the run-out period (Table 2). The 90% CI 
for the difference between treatments at all time points 
remained well within the predefined equivalence range of 
+__ 10 beats min-~, confirming that the two treatments were 
equivalent (Table 2). 
ADVERSE EVENTS 
A similar percentage of patients in both groups reported at 
least one adverse vent during treatment: 32% in the HFA 
134a pMDI group and 36% in the CFC pMDI group. Most 
of these events were related to the patients' underlying 
asthma (Table 3). In the HFA 134a and CFC pMDI 
groups, respectively, 25 (9%) and 17 patients (6%) reported 
an adverse vent which was assessed by the investigator as 
drug-related, the most common being related to the taste of 
the inhaler (12 and four patients, respectively). 
Adverse events typically associated with salbutamol 
(tachycardia nd tremors) were reported by <1% of 
patients in each treatment group. During treatment, serious 
adverse vents were reported by six patients in the HFA 
134a pMDI group and two patients in the CFC pMDI 
group. None of these were considered related to the study 
medication. 
Laboratory analyses revealed no findings of any clinical 
significance during the study. There was evidence of a 
small, non-significant decrease in serum potassium levels 
from baseline in both groups ( -0-08 and -0 .07 mmol I - i  
in the HFA 134a and CFC pMDI group, respectively) 
(Table 4). Hepatic function was not affected and measure- 
ment of all other safety parameters including ECG and 
blood pressure indicated no difference between the two 
groups. 
TABLE 1. Patient demographic characteristics 
Salbutamol Salbutamol 
HFA 134a pMDI CFC pMDI 
Number of patients 277 270 
Sex (no. of patients): 
Males 107 (39%) 116 (43%) 
Females 170 (61%) 154 (57%) 
Age (years): 
Mean+so 42+ 14 44+ 14 
Range 18-73 18-7 I
Use of Volumatic TM spacer (no. of patients): 46 (17%) 50 (19%) 
History of smoking (no. of patients): 
Never 201 (73%) 202" (75%) 
Ex-smoker 64 (23%) 52 (19%) 
Current 11 (4%) 16 (6%) 
Baseline FEVI (1): mean+so: 2.51 +0.78 2"44+0-78 
Asthma medication continued into the study (no. of patients): 
Inhaled corticosteroids 148 (54%) 149 (55%) 
Methlyxanthines 126 (45%) 27 (10%) 
Sodium cromoglycate 34 (12%) 120 (44%) 
CFC, chlorofluorocarbon; FEVt, forced expiratory volume in 1 sec; HFA, hydrofluoroalkane; pMDI, pressurized metered 
dose inhaler; so, standard eviation. 
TABLE 2. Change in heart rate during treatment (beats rain-~) 
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Salbutamol 
HFA 134a 
pMDI 
Salbutamol Difference 90% CI P-value* 
CFC pMDI (+ SE) 
Treatment: week 1 
Number of patients 276 
Baseline mean + SD 75 +9 
Adjusted* mean change _+ SE I ±0 
Treatment: week 12 
Number of patients 269 
Baseline mean ± SD 75± 10 
Adjusted* mean change ± SE 2 +0 
Run-out: week 1 
Number of patients 265 
Baseline mean ± SD 75±9 
Adjusted* mean change _+ SE 1 ±0 
269 
75+9 
1+0 0+1 --1, l 0.855 
265 
75+9 
1+_0 1±1 0, 2 0-190 
264 
75±9 
1±0 0±1 --2, 1 0"504 
*P-value calculated using analysis of covariance. 
* Adjusted for baseline, gender, age and centre. 
CFC, chlorofluorocarbon; CI, confidence interval; 
SD, standard eviation; SE, standard error. 
HFA, hydrofluoroalkane; pMDI, pressurized metered dose inhaler; 
TABLE 3. Most common (>_4% of patients) adverse vents during treatment 
Salbutamol Salbutamol 90% CI 
HFA 134a pMDI CFC pMDI for difference in 
incidence 
Number of patients 277 270 
Number of patients reporting an adverse vent 89 (32%) 98 (36%) 
Asthma 32 (12%) 29 (11%) -3.61, 5.24 
Headache 12 (4%) 14 (5%) -3.85, 2-14 
Bronchitis 12 (4%) 8 (3%) -- 1.26, 4.00 
Unpleasant taste 12 (4%) 4 (1%) 0.50, 5.20 
Nasopharyngitis I1 (4%) 16 (6%) --5.01, 1.10 
Sore throat 8 (3%) 12 (4%) -4-20, 1.09 
CFC, chlorofluorocarbon; CI, confidence interval; HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler. 
TABLE 4. Change in serum potassium levels during treatment 
Serum potassium level (mmol 1-i) 
Salbutamol HFA 134a pMDI 
(n = 248) 
Salbut_amol CFC pMDI 
(n = 242) 
Baseline (90% CI) 
Treatment period: week 12 (90% CI) 
Mean change 
4.43 (3.40, 5.80) 4.45 (3-20, 5.90) 
4.35 (3.30, 5-50) 4.38 (3.10, 5-70) 
- 0.08 - 0-07 
CFC, chlorofluorocarbon; CI, confidence interval; HFA, hydrofluoroalkane; pMDI, pressurized metered ose inhaler. 
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DIARY CARD DATA 
There was a similar increase in mean morning PEF in both 
treatment groups during the 12-week treatment period. 
After 12 weeks of treatment, he adjusted mean change 
from baseline was 161min -1 in the HFA 134a pMDI 
group and 101min - t  in the CFC pMDI group. The 90% 
CI for the treatment difference at 12 weeks ( -  1, 131 min-  l) 
indicated comparability between treatments. Statistical 
analysis also confirmed that the treatments were compar- 
able throughout the study: the 90% CI for the difference 
between groups was -3 ,  6 1 min-I  after week 1 of the 
treatment period and - 3, 5 1 min-  ~ after week I of the run- 
out period. 
All other PEF variables and symptom scores were 
comparable between the two groups during the treatment 
and run-out periods. The percentage of days and nights 
When patients required no additional bronchodilator 
therapy gradually increased to a similar extent in both 
groups during the treatment period (90% CI 0, 0). 
The use of a spacer device had no significant effect on 
diary card parameters in either group. 
CLINIC LUNG FUNCTION 
FEVI values at all clinic visits were comparable between the 
two treatment groups with mean values within the range 
2.44 to 2"56 1 (Table 5). Clinic visit PEF values were also 
comparable between treatment groups. 
FIRST DOSE EFFECT 
After the first dose of study medication, the majority of 
patients experienced either no change or a positive change 
in clinic PEF. The frequency distribution of response was 
similar in the two groups (Fig. 1). PEF decreased in 20 
patients (7%) in the HFA 134a pMDI group in 21 patients 
(8%) in the CFC pMDI group. At the end of the 12-week 
treatment period, when all patients received the salbutamol 
CFC pMDI, PEF decreased in 15 (5%) and 17 patients 
(6%), respectively. 
Discussion 
As CFC propellants are gradually phased out, millions of 
patients will have to change from their current CFC- 
formulated pMDI to a non-CFC alternative. In addition, 
prior to the phase out, both formulations will be 
commercially available with the possibility that patients 
may receive both formulations together or be switched 
between them. Therefore, it is important o determine 
whether the switch will pose any problem for patients and 
whether the two products may be considered to be entirely 
interchangeable in terms of tolerability and efficacy. The 
objective of this study was to address these issues. 
A number of difficulties known to be inherent o the 
design of a 'switch study' make this mode of research 
relatively unsatisfactory. However, certain questions can- 
not be answered without the type of before and after 
comparisons, which are the basis of a switch study. Here 
the objective was to assess the effect of switching from a 
salbutamol CFC-propelled pMDI to the same medication 
propelled by a non-CFC alternative and then switching 
back to the CFC pMDI. In this study patients received the 
highest recommended dose of salbutamol (200 lLg four times 
daily) which is still widely used in some countries, albeit it 
contrary to asthma management guidelines. For compara- 
tive purposes, a control group of patients received the CFC 
formulated product (propellants I 1 and 12) throughout the 
study. 
Heart rate was chosen as the primary outcome measure 
rather than lung function, on the basis that lung function 
was likely to be maximal because patients were receiving the 
highest recommended dose of salbutamol. However, heart 
rate is known to increase with continued administration f 
high doses of fl2-agonists (5). In this study there was a slight 
increase in mean heart rate after 12 weeks of treatment with 
both formulations, 2 beats min -~ in the HFA 134a pMDI 
group and 1 beat min- i  in the CFC pMDI group. A slight 
increase (1 beatmin - j )  was also reported when patients 
randomized to the HFA 134a pMDI were switched back to 
the CFC pMDI during the 4-week run-out period. 
Interestingly, this small increase was comparable to the 
change in heart rate in the non-switched group who 
received the same propellant (CFC) throughout the study. 
TABLE 5. Clinic visit lung function measurements 
Mean FEVI +SO (I) Mean PEF __+ so (1 min- i )  
Salbutamol Salbutamol Salbutamol Salbutamol 
HFA 134a pMDI CFC pMDI HFA 134a pMDI CFC pMDI 
Baseline 2.51 +0.78 2.44-1-0-78 406+ 117 404-t- 107 
Treatment period: week 12 2.49-t-0.86 2-47+0.79 397+ !12 405+ 110 
Run-out: week l 2-54-1-0-88 2-49-t-0.82 401 + 113 406___ 114 
Run-out: week 4 2-56+0.84 2.51 -t-0.83 409+ 112 407+ 107 
CFC, chlorofluorocarbon; FEVI forced expiratory volume in 1 sec; HFA, hydrofluoroalkane; pMDI, pressurized metered 
dose inhaler; PEF, peak expiratory flow; so, standard eviation. 
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FIG I. Frequency distribution of the percentage change in peak expiratory flow (PEF) 5 min after inhalation of the first dose 
of salbutamol 200/lg propelled either by the hydrofluoroalkane propellant HFA 134a ([-3) or the chlorofluorocarbon (CFC) 
propellants 11 and 12 (.).  
With respect to changes in heart rate, the two formulations 
were shown to be equivalent as the 90% CI for the 
treatment differences at all times points were well within the 
predefined criteria for equivalence (+_10 beats rain-S). 
These data are supported by the lack of a significant 
difference in serum potassium levels or blood pressure 
between the two treatment groups. 
From the similarity of the adverse vents profile in both 
treatment groups there was no indication that the new 
propellant might interact with salbutamol in a manner 
likely to reduce the safety of the salbutamol HFA 134a 
pMDI. However, more patients in the HFA 134a pMDI 
group did report adverse vents related to the taste of the 
inhaler (12 vs. four patients in the CFC pMDI group), 
possibly because these patients witched treatments during 
the trial whereas patients in the CFC pMDI group did not. 
Experienced salbutamol CFC pMDI users will have certain 
perceptions that any small change will highlight. It is 
anticipated that pMDIs reformulated with the propellant 
HFA 134a may taste different o some patients. However, 
the formulation of the product employed in this study does 
not contain any excipients (e.g. surfactants or alcohol) that 
are used in other salbutamol HFA products (6). It is 
envisaged that this should minimize the impact of a 
difference in taste. Furthermore, it is important o educate 
patients to these slight differences as new products become 
available (7). 
A further important marker of tolerability in this study 
was the incidence of paradoxical bronchospasm. This is a 
recognized adverse event associated with pressurized 
inhalers, although the incidence tends to be low (1.5%) 
(8). Analysis of the PEF response after administration of 
the first dose of study medication in each treatment period 
showed that a similar number of patients in the HFA 134a 
and CFC pMDI groups experienced a reduction in PEF of 
up to 40% after inhalation (9% and 8%, respectively). 
However, no patient reported paradoxical bronchospasm 
as an adverse vent. 
Efficacy parameters were analysed as secondary variables 
in this study. There was an unexpected increase in mean 
morning PEF in both treatment groups, which may have 
been attributable to an increase in compliance with 
treatment, a phenomenon often observed in clinical trials. 
All other diary card parameters were comparable for the 
two formulations as was clinic FEVI. A small difference in 
clinic PEF was reported between the two groups at week 12; 
however, clinic PEF was measured infrequently and there- 
fore this isolated result is of limited importance. These data 
are supported by the results of previous studies showing 
equivalent morning or clinic PEF results during treatment 
with salbutamol formulated in an HFA 134a and CFC 
pMDI (9-12). 
In conclusion, this study did not detect any deleterious 
effects associated with switching from treatment with 
salbutamol as currently formulated (with CFC propellants 
I I and 12) to salbutamol formulated with the non-CFC 
propellant HFA 134a, or vice versa. Both formulations were 
found to be equivalent in terms of tolerability and to have 
comparable efficacy when taken by adult patients with mild 
to moderate asthma at a dose of 200 pg four times daily. 
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